## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.13 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-4.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($94.30)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 3, 2025**
- Source: BioSpace | 20251204T101641 | Neutral | Relevance: 100%
- Incyte Corporation announced equity inducement awards to Richard Hoffman, their new Executive Vice President and General Counsel, under Nasdaq Listing Rule 5635(c)(4). These awards, effective December 1, 2025, include stock options, restricted stock units, and performance shares, designed to incentivize his employment. The grants are part of the Company’s 2024 Inducement Stock Incentive Plan.

**2. Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)**
- Source: Business Wire | 20251204T090939 | Somewhat-Bullish | Relevance: 100%
- Incyte Corporation announced equity inducement awards for Richard Hoffman, the new Executive Vice President and General Counsel, as detailed under Nasdaq Listing Rule 5635(c)(4). These awards, approved by the compensation committee, include stock options, restricted stock units (RSUs), and performance shares, granted as a material inducement for his employment. The grants are subject to vesting schedules and continued service with the company.

**3. VP Stein Sells 22,664 ($2.3M) Of Incyte Corp [INCY]**
- Source: TradingView | 20251204T050906 | Somewhat-Bearish | Relevance: 100%
- Steven H. Stein, Vice President of Incyte Corp [INCY], filed a Form 4 disclosing the sale of 22,664 shares valued at $2,324,438 between December 1-2, 2025, executed pursuant to a prearranged trading plan. Additionally, 17,093 shares were surrendered to cover option exercise costs and tax liability. After these transactions, Stein's direct holdings amount to 63,129 shares.

**4. Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)**
- Source: Markets Financial Content | 20251203T213000 | Somewhat-Bullish | Relevance: 100%
- Incyte Corporation announced equity inducement awards granted to Richard Hoffman, its new Executive Vice President and General Counsel. These awards, approved by the compensation committee, are an inducement for his employment in accordance with Nasdaq Listing Rule 5635(c)(4) and include stock options, restricted stock units, and performance shares.

**5. Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)**
- Source: Yahoo Finance Singapore | 20251203T213000 | Neutral | Relevance: 100%
- Incyte Corporation announced equity inducement awards to Richard Hoffman, the Company’s new Executive Vice President and General Counsel, under Nasdaq Listing Rule 5635(c)(4). These awards, approved by the compensation committee, include stock options to purchase 43,301 shares, restricted stock units for 9,466 shares, and performance shares with a target of 23,665 shares. The grants, effective December 1, 2025, are an inducement for his employment, with vesting schedules tied to continued service and company performance.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Barclays | $115 | $101 | +14% |
| 2025-11-04 | Piper Sandler | $102 | $82 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Barclays | main | Overweight |
| 2025-11-04 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.05M) |
| Sells | 20 ($25.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.6% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $26M sold (20 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Forward P/E 13.1x attractive for 14% earnings growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (2 raises, avg +19%). Insider selling cluster ($25.8M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.7B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 7.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 13.1 |
| Current P/E | 14.9 |
| YoY Growth | 13.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -1.0% to -5.6% (-4.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.6pp (needs >4.0% for momentum thesis). AM_20 at -3.6% indicates price below own 20MA trend. Underperforming sector by 4.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.31x) but short-term weakness (below SMA20). MACD histogram bearish (-1.07), momentum weakening. RSI neutral at 49. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.58% (CS: 6) | Weak |
| RSI_14 | 49.1 | Neutral |
| MACD Histogram | -1.07 | Bearish |
| vs SMA20 | 0.964x | Below |
| vs SMA50 | 1.057x | Above |
| vs SMA200 | 1.315x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $100.46
- **Stop Loss:** $94.30 (6.1% risk)
- **Target:** $112.78 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 81
- **Position Value:** $8,137.26
- **Portfolio %:** 8.14%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*